MAP2K1 and leukemia: Furthermore, they proved that both proximal and compound CSF3R mutations relied on enhanced MAPK signaling for oncogenic transformation and effectively abrogated leukemia development in mice expressing either of these mutational variants by targeting Mek1/2 with Trametinib123.